Systemic therapies in atopic dermatitis: The pipeline
- 1 July 2017
- journal article
- review article
- Published by Elsevier in Clinics in Dermatology
- Vol. 35 (4) , 387-397
Abstract
No abstract availableKeywords
This publication has 119 references indexed in Scilit:
- A randomized phase 2a efficacy and safety trial of the topical J anus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasisBritish Journal of Dermatology, 2013
- Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiencyJournal of Allergy and Clinical Immunology, 2012
- Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic responseJournal of Allergy and Clinical Immunology, 2011
- Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genesJournal of Allergy and Clinical Immunology, 2009
- IL-22–producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17–producing TH17 T cellsJournal of Allergy and Clinical Immunology, 2009
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6Clinical Immunology, 2008
- Etanercept is minimally effective in 2 children with atopic dermatitisJournal of the American Academy of Dermatology, 2005
- Human epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLPNature Immunology, 2002